CagriSema vs Semaglutide
A side-by-side research comparison of CagriSema and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Semaglutide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | Combination product | 4,114 Da |
| Half-life | 7 days (both components) | 7 days (168 hours) |
| Bioavailability | High (SubQ) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.